Factors predicting survival in advanced T-staged hepatocellular carcinoma patients treated with reduction hepatectomy followed by transcatheter arterial chemoembolization

European Journal of Surgical Oncology

Volumn 33, Issue 8, 2007, Pages 1019-1024

  Kobayashi, A ^a   Takahashi, S ^a   Ishii, H ^a   Konishi, M ^a   Nakagohri, T ^a   Gotohda, N ^a   Satake, M ^a   Furuse, J ^a   Kinoshita, T ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Hepatocellular carcinoma; Prognosis; Resection; Transcatheter arterial chemoembolization; Transcatheter arterial embolization

Indexed keywords

ALPHA FETOPROTEIN; EPIRUBICIN; INDOCYANINE GREEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MALE; OVERALL SURVIVAL; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL RATE;

ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHEMOTHERAPY, ADJUVANT; EPIRUBICIN; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34548633762     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2007.02.023     Document Type: Article

References (31)

1. Okuda K., Ohtsuki T., Obata H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56 (1985) 918-928
2. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 28 (1998) 751-755
3. Ikai I., Arii S., Kojiro M., et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 101 (2004) 796-802
4. Fan S.T., Lo C.M., Liu C.L., et al. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 229 (1999) 322-330
5. Torzilli G., Makuuchi M., Inoue K., et al. No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach. Arch Surg 134 (1999) 984-992
6. Ng K.K., Vauthey J.N., Pawlik T.M., et al. International Cooperative Study Group on Hepatocellular Carcinoma. Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 12 (2005) 364-373
7. Llovet J.M., Real M.I., Montaña X., et al. Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 (2002) 1734-1739
8. Llovet J.M., and Bruix J. for the Barcelona-Clinic Liver Cancer Group. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37 (2003) 429-442
9. Mondazzi L., Bottelli R., Brambilla G., et al. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology 19 (1994) 1115-1123
10. Taniguchi K., Nakata K., Kato Y., et al. Treatment of hepatocellular carcinoma with transcatheter arterial embolization. Analysis of prognostic factors. Cancer 73 (1994) 1341-1345
11. Shimamura Y., Gunven P., Ishii M., Ono M., and Abe K. Debulking surgery and arterial embolization for unresectable liver cancer. Hepatogastroenterology 40 (1993) 10-13
12. Yamamoto M., Iizuka H., Matsuda M., Nagahori K., Miura K., and Itakura J. The indications for tumor mass reduction surgery and subsequent multidisciplinary treatments in stage IV hepatocellular carcinoma. Surg Today 23 (1993) 675-681
13. Yamamoto K., Takenaka K., Kawahara N., et al. Indications for palliative reduction surgery in advanced hepatocellular carcinoma. The use of a remnant tumor index. Arch Surg 132 (1997) 120-123
14. Nagashima J., Okuda K., Tanaka M., Sata M., and Aoyagi S. Prognostic benefit in cytoreductive surgery for curatively unresectable hepatocellular carcinoma - comparison to transcatheter arterial chemoembolization. Int J Oncol 15 (1999) 1117-1123
15. Wakabayashi H., Ushiyama T., Ishimura K., et al. Significance of reduction surgery in multidisciplinary treatment of advanced hepatocellular carcinoma with multiple intrahepatic lesions. J Surg Oncol 82 (2003) 98-103
16. Ku Y., Iwasaki T., Tominaga M., et al. Reductive surgery plus percutaneous isolated hepatic perfusion for multiple advanced hepatocellular carcinoma. Ann Surg 239 (2004) 53-60
17. Inoue K., Nakamura T., Kinoshita T., et al. Volume reduction surgery for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 130 (2004) 362-366
18. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 2nd English ed (2003), Kanehara & Co. Ltd., Tokyo, Japan
19. Pugh R.N., Murray-Lyon I.M., Dawson J.L., Pietroni M.C., and Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60 (1973) 646-649
20. Lau H., Man K., Fan S.T., Yu W.C., Lo C.M., and Wong J. Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Br J Surg 84 (1997) 1255-1259
21. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
22. Cox D.R. Regression models and life tables (with discussion). J R Stat Soc B 34 (1972) 187-220
23. Poon R.T., Fan S.T., Ng I.O., and Wong J. Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification. Ann Surg 237 (2003) 376-383
24. Ikai I., Yamaoka Y., Yamamoto Y., et al. Surgical intervention for patients with stage IV-A hepatocellular carcinoma without lymph node metastasis: proposal as a standard therapy. Ann Surg 227 (1998) 433-439
25. Nomura F., Ohnishi K., and Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer 64 (1989) 1700-1707
26. Ota H., Nagano H., Sakon M., et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 93 (2005) 557-564
27. Sakon M., Nagano H., Dono K., et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 94 (2002) 435-442
28. Leung T.W., Tang A.M., Zee B., et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 94 (2002) 421-427
29. Yeo W., Mok T.S., Zee B., et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97 (2005) 1532-1538
30. Chung Y.H., Song I.H., Song B.C., et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 88 (2000) 1986-1991
31. Ando E., Yamashita F., Tanaka M., and Tanikawa K. novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 79 (1997) 1890-1896